2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Neoplasm Metastasis
19
Neoplasms
17
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Liver Neoplasms
8
Glioblastoma
7
Sarcoma
6
Stomach Neoplasms
5
Sarcoma, Ewing
5
Ovarian Neoplasms
5
Osteosarcoma
5
Melanoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Rhabdomyosarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Leukemia, Myeloid, Acute
3
Colorectal Cancer Metastatic
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Advanced Colorectal Cancer
3
Thyroid Neoplasms
2
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
regorafenib
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled